Abstract
The functionalization of nanoparticles (NPs) with cell penetrating peptides (CPPs) constitutes a breakthrough for the intracellular delivery of therapeutic and diagnostic payloads. In late 1998, a significant cellular uptake of a small protein from the HIV-1 virus, namely TAT peptide (TATp), was observed. Thereafter, research began on design of similarly acting peptides, and the coupling of NPs with these novel CPPs. Here, we describe recent methods used to modify the surface of NPs with CPPs and the in vitro and in vivo effects of such functionalization on the intracellular delivery of various cargos. In particular, we highlight recent advances aimed at reducing the non-selectivity of CPPs and the prevention of their enzymatic cleavage en route to target tissues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189–1193
Derossi D, Joliot AH, Chassaing G et al (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444–10450
Futaki S, Suzuki T, Ohashi W et al (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836–5840
Pooga M, Hällbrink M, Zorko M et al (1998) Cell penetration by transportan. FASEB J 12:67–77
Schwarze SR, Ho A, Vocero-Akbani A et al (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1572
Fonseca SB, Pereira MP, Kelley SO (2009) Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61:953–964
Huang Y, Jiang Y, Wang H et al (2013) Curb challenges of the “Trojan Horse” approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev 65:1299–1315
Choi YS, David AE (2014) Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol 15:192–199
Josephson L, Tung CH, Moore A et al (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 10:186–191
Wunderbaldinger P, Josephson L, Weissleder R (2002) Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 13:264–268
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160
Lasic DD, Papahadjopoulos D (1995) Liposomes revisited. Science 267:1275–1276
Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756
Maeda H, Bharate GY, Daruwalla J (2008) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419
Torchilin VP, Rammohan R, Weissig V et al (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 98:8786–8791
Pappalardo JS, Langellotti CA, Di Giacomo S et al (2014) In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes. Int J Nanomedicine 9:963–973
Lukyanov AN, Gao Z, Mazzola L et al (2002) Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 19:1424–1429
Lukyanov AN, Hartner WC, Torchilin VP (2004) Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release 94:187–193
Sawant RR, Torchilin VP (2009) Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374:114–118
Sethuraman VA, Bae YH (2007) TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 118:216–224
Sawant RR, Sawant RM, Kale AA et al (2008) The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J Drug Target 16:596–600
Koren E, Apte A, Sawant RR et al (2011) Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv 18:377–384
Koren E, Apte A, Jani A et al (2012) Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 160:264–273
Apte A, Koren E, Koshkaryev A, Torchilin VP (2014) Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biol Ther 15:69–80
Zhu L, Kate P, Torchilin VP (2012) Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6:3491–3498
Ishida T, Iden D, Allen TM (1999) A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 460:29–133
Zhu L, Wang T, Perche F et al (2013) Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A 110:17047–17052
Acknowledgments
The authors thank Dr. William C. Hartner for the help in the manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Salzano, G., Torchilin, V.P. (2015). Intracellular Delivery of Nanoparticles with Cell Penetrating Peptides. In: Langel, Ü. (eds) Cell-Penetrating Peptides. Methods in Molecular Biology, vol 1324. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2806-4_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2806-4_24
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2805-7
Online ISBN: 978-1-4939-2806-4
eBook Packages: Springer Protocols